CYP2J2

Across TCGA pan-cancer cohorts, CYP2J2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of CYP2J2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where CYP2J2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CYP2J2 is over-expressed in tumor, although a few such as HNSC and COAD show the opposite, repressed pattern.

CCRCC, HNSC, and COAD are the cancer types where CYP2J2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CYP2J2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	IV	+1.617	<.001	12	view →
HNSC	All	All	−0.442	.001	8	view →
COAD	All	All	−0.538	.003	6	view →
LUAD	Male	All	+0.508	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

CYP2J2–CCRCC

Open the CCRCC breakdown →